It exhibited a significant tumoricidal effect against RCC by inhibiting NF-κB and activating p53; reduced cell viability and decreased tumor volume in melanoma xenograft mouse models; induced apoptosis in leukemia cells by depolarization of mitochondria, oxidative stress and downregulation of Bcl-2 and Bcl-2L; and inhibited cell growth and cell cycle progression in gastric cancer cells via activating p53 and caspase-3 dependent apoptotic pathways [121–124]. Here, TP53 is linked to renal cell carcinoma.